May 24, 2024 07:15 AM EDTUpdated 08:02 AM R&DPharma AUTHORKatherine LewinNews Reporterklewin@endpointsnews.com Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2 diabetes and chronic kidney disease, building the company’s case for expanding the drug in a broad range of...
Tag: <span>Kidney disease</span>
Post
Simple measurement can predict risk of worsening of widespread kidney disease
by Aarhus University Graphical Abstract. Credit: Nephrology Dialysis Transplantation (2024). DOI: 10.1093/ndt/gfad271About ten percent of the Danish population suffers from chronic kidney disease, and some individuals experience rapid deterioration after the diagnosis is made. Now, a team of researchers from Aarhus University in a comprehensive study has investigated the precise risk of rapid progression, and the...
Post
Significant benefit seen in Phase III trial of experimental drug for kidney disease
by University of Washington School of Medicine Credit: Pixabay/CC0 Public Domain In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria—albumin in urine, a sign of kidney damage—for 50% of participants. When the experimental drug was paired with a standard-care medication, 70% of participants reportedly experienced a significant reduction in...
Post
Guidance for prevention, diagnosis, evaluation, treatment of hepatitis C virus in chronic kidney disease
by American College of Physicians Credit: CC0 Public Domain The latest clinical practice guideline from the Kidney Disease: Improving Global Outcomes (KDIGO) organization offers guidance for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) in chronic kidney disease (CKD). The guideline is a targeted update to 2018 recommendations on the same topic and...
Post
Chronic kidney disease raises risk of sudden cardiac arrest among Hispanics and Latinos
By Anika NayakOct. 11, 2023 APSTOCKChronic kidney disease was the strongest risk factor for sudden cardiac arrest among Hispanic and Latino adults in the first study to evaluate this population in the U.S. for risk factors of this major cause of death. Researchers from Cedars–Sinai Medical Center in Los Angeles identified clinical predictors that influence...
Post
Study confirms pioneering drug highly effective for rare kidney disease
by Newcastle University Credit: Pixabay/CC0 Public DomainA pioneering drug for a rare kidney disease prevents organ failure and significantly improves the outcome for patients, new research has confirmed. Atypical hemolytic uraemic syndrome (aHUS) is a genetic life-threatening condition caused by a defect in the immune system which leads to kidney failure. Newcastle University, UK, carried...
Post
Gene therapy hope for children with kidney disease
by University of Bristol Image [left to right]: Professor Moin Saleem, Dr Wen Ding [Academic Clinical Lecturer in Paediatric Renal Medicine] and Professor Gavin Welch [Professor of Renal Cell Biology] from the University of Bristol’s Medical School Credit: Kidney Research UK Researchers at the University of Bristol have made a remarkable step forward in finding a potential cure for...
Post
New algorithm can predict diabetic kidney disease
by Sanford Burnham Prebys Medical Discovery Institute Association between CpG methylation and renal function. The methylation level of each CpG site was tested for its association with baseline eGFR (a–c) and eGFR slope (d–f). The results of all the 434,908 CpG sites analyzed in this study are shown using Manhattan plots (a, d), quantile–quantile (QQ) plots (b, e),...
Post
Inflammation ‘brake’ gene may help reveal outcomes of kidney disease
by Garvan Institute of Medical Research Paradoxically, a gene variant that increases inflammation also has a protective effect on the kidneys. Seen here, kidney cell nuclei (blue) and an influx of immune regulatory cells (pink) that prevent damage in an injured kidney. Credit: Garvan A discovery about gene variants of an inflammation ‘brake’ brings scientists a step...
Post
First-in-class treatment delivers major advance for incurable kidney disease
by George Institute for Global Health Credit: Unsplash/CC0 Public Domain The latest findings from the PROTECT phase III trial show sparsentan—a novel treatment for IgA nephropathy—significantly reduces proteinuria, or abnormal protein levels in the urine, compared to standard treatment irbesartan. The interim analysis of data from the PROTECT trial was published April 1 in The Lancet and simultaneously...